Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary CNS Lymphoma After Autologous HSCT
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant
JAMA Oncol 2021 May 06;[EPub Ahead of Print], M Scordo, TP Wang, KW Ahn, Y Chen, S Ahmed, FT Awan, A Beitinjaneh, A Chen, VA Chow, B Dholaria, N Epperla, U Farooq, N Ghosh, N Grover, N Hamad, GC Hildebrandt, L Holmberg, S Hong, DJ Inwards, A Jimenez-Jimenez, R Karmali, VP Kenkre, F Khimani, E Klyuchnikov, MM Krem, PN Munshi, Y Nieto, T Prestidge, P Ramakrishnan Geethakumari, AR Rezvani, PA Riedell, S Seo, NN Shah, M Solh, JA Yared, MA Kharfan-Dabaja, A Herrera, M Hamadani, CS SauterFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.